[Expression of CLAUDIN-11 in the testicular tissue of the patient with non-obstructive azoospermia and its clinical significance].

Objective: To study the expression of CLAUDIN-11 in the testis tissue of non-obstructive azoospermia (NOA) patients with different severities and investigate its clinical significance.

Methods: Sixty-two NOA patients were divided into a hypospermatogenesis (HS) group (n = 30) and a Sertoli cell only syndrome (SCO) group (n =32). The expression of CLAUDIN-11 in the testicular tissue of the patients was detected by immunohistochemistry, that of CLAUDIN-11 mRNA determined by real-time fluorescence quantitative polymerase chain reaction (RT-qPCR), and the levels of serum reproductive hormones measured by chemiluminescent immunoassay.

[Shengjing tablets for semen non-liquefaction: a clinical study of 100 cases].

Objective: To investigate the efficacy and action mechanism of Shengjing Tablets in the treatment liquefaction.

Methods: We randomly assigned 150 patients with semen non-liquefaction to receive Shengjing Tablets group, n = 100) and vitamin E capsules (control group, n = 50) for 2 courses of 45 days each, followed by observation liquefaction time and other semen parameters.

Results: After the first course, 68 of the patients in the treatment group 20 responded and 12 failed to respond; and after the second course, 84 were cured, 9 responded and 7 failed to respond, effective rate of 93.

[Expression of TEKT4 protein decreases in the ejaculated spermatozoa of idiopathic asthenozoospermic men].

Objective: To investigate the role of the TEKT4 protein in the pathogenesis of idiopathic asthenozoospermia.

Methods: We separated and purified the ejaculated sperm from idiopathic asthenozoospermia patients and normozoospermic men by Percoll discontinuous density gradients, and detected the distribution and the expressions of TEKT4 mRNA and TEKT4 protein by RT-PCR and Western blot.

Results: RT-PCR revealed that the expression of TEKT4 mRNA was significantly lower in the sperm of the idiopathic asthenozoospermia patients than in those of the normozoospermic men (0.

[Expression of SEPT4 protein in the ejaculated sperm of idiopathic asthenozoospermic men].

Objective: To investigate the role of the SEPT4 protein in the pathogenesis of idiopathic asthenozoospermia.

Methods: Samples of ejaculated sperm from idiopathic asthenozoospermia patients and normozoospermic men were separated and purified by Percoll discontinuous density gradients, the distribution and expression of SEPT4 in the sperm samples were determined by immunocytochemistry, and the expressions of SEPT4 mRNA and SEPT4 protein were detected by RT-PCR and Western blot.

Results: Immunocytochemistry showed that the expression of SEPT4, located in the annulus, was significantly reduced in the sperm of the idiopathic asthenozoospermia patients (t = 3.

[CatSper1 protein and idiopathic asthenozoospermia].

Objective: To investigate the role of the cation channel of sperm 1 (CatSper1) protein in the pathogenesis of idiopathic asthenozoospermia.

Methods: Sperm samples from patients with idiopathic asthenozoospermia were separated by Percoll discontinuous density gradients, and the distribution and expression of the CatSper1 protein were determined by immunocytochemistry. Western blotting was used to detect the different expressions of CatSper1 in the ejaculated sperm from the normal control, mild asthenozoospermia, moderate asthenozoospermia and severe asthenozoospermia groups, followed by statistical analyses.

[Hypoxia-inducible factor 1 and prostate cancer].

Hypoxia-inducible factor 1 (HIF-1) has a close relation with prostate cancer. It is involved not only in angiogenesis, cell proliferation/survival and glucose metabolism but also in p53, p21 and signal transduction pathway in prostate cancer. Further studies of HIF-1 may yield new approaches to the diagnosis and treatment of prostate cancer.

[RNA interference inhibits VEGF expression and growth of PC-3 in prostate carcinoma].

Objective: To construct a eukaryotic expression vector carrying human VEGF RNAi and to study the effect of RNA interference on VEGF expression in prostate carcinoma.

Methods: VEGF RNAi was synthesized, inserted into the RNA interference eukaryotic expression vector, and confirmed by the result sequencing. The vector was transfected into prostate cancer PC-3, the VEGF expression detected by Western blot and the cell inhibiting rate determined by MTT.